Clinical and treatment patterns in neuromyelitis optica: a retrospective study from a single centre

Authors

  • Kamlesh A. Jagiasi Department of Neurology, Grant Government Medical College and Sir JJ Group of Hospitals, Mazgaon, Mumbai, Maharashtra, India
  • Shashank Nagendra Department of Neurology, Grant Government Medical College and Sir JJ Group of Hospitals, Mazgaon, Mumbai, Maharashtra, India
  • Afroz Ansari Department of Neurology, Grant Government Medical College and Sir JJ Group of Hospitals, Mazgaon, Mumbai, Maharashtra, India
  • Prachi Barvalia Department of Neurology, Grant Government Medical College and Sir JJ Group of Hospitals, Mazgaon, Mumbai, Maharashtra, India
  • Vikram Aglave Department of Neurology, Grant Government Medical College and Sir JJ Group of Hospitals, Mazgaon, Mumbai, Maharashtra, India

DOI:

https://doi.org/10.18203/2349-3933.ijam20193285

Keywords:

Neuromyelitis optica, Optic neuritis, Rituximab, Transverse myelitis

Abstract

Background: The aim of the study was to study the different presentations, treatment patterns and relapses on therapy in patients of neuromyelitis optica (NMO) and neuromyelitis optica spectrum disorder (NMOSD).

Methods: This is a retrospective, observational study in a tertiary hospital where Demographics, clinical manifestations at onset and at follow up and relapses, serum anti Aquaporin 4 antibody status, first line immunomodulatory therapy which was initiated and Relapses on first line therapy were noted.

Results: Demographics and clinical presentation was largely similar to published data. 80% patients presented with LETM/ON at onset. Ten patients relapsed on oral therapy and trend was to shift from oral therapy to RTX after relapse on oral agent. No relapses were noted on RTX.

Conclusions: Unaffordability and apprehension towards injections and cost were the factors affecting IMT decision, so majority received oral agents Aza/ MMF as first line therapy while remaining patients on oral therapy remained relapse free.

References

Wingerchuk DM, Hogancamp WF, O’brien PC, Weinshenker BG. The clinical course of neuromyelitis optica (Devic’s syndrome). Neurol. 1999;53(5):1107.

Lennon VA, Wingerchuk DM, Kryzer TJ, Pittock SJ, Lucchinetti CF, Fujihara K, et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet. 2004;364(9451):2106-12.

Lucchinetti CF, Mandler RN, McGavern D. A role for humoral mechanisms in the pathogenesis of Devic’s neuromyelitis optica. Brain. 2002;125:1450-61.

Lee DH, Metz I, Berthele A, Stadelmann C, Brück W, Linker RA, et al. Supraspinal demyelinating lesions in neuromyelitis optica display a typical astrocyte pathol. Neuropathol Applied Neurobiol. 2010;36(7):685-7.

Lennon VA, Kryzer TJ, Pittock SJ, Verkman AS, Hinson SR. IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med. 2005;202(4):473-7.

Papadopoulos MC, Bennett JL, Verkman AS. Treatment of neuromyelitis optica: state-of-the-art and emerging therapies. Nature Rev Neurol. 2014;10(9):493.

Damato V, Evoli A, Iorio R. Efficacy and safety of rituximab therapy in neuromyelitis optica spectrum disorders: a systematic review and meta-analysis. JAMA Neurol. 2016;73(11):1342-8.

Iorio R, Damato V, Alboini PE, Evoli A. Efficacy and safety of rituximab for myasthenia gravis: a systematic review and meta-analysis. J Neurol. 2015;262(5):1115-9.

Jacob A, Weinshenker BG, Violich I, McLinskey N, Krupp L, Fox RJ, et al. Treatment of neuromyelitis optica with rituximab. Arch Neurol. 2008;65(11):1443-8.

Mandler RN, Davis LE, Jeffery DR, Kornfeld M. Devic's neuromyelitis optica: a clinicopathological study of 8 patients. Annals of Neurology: Official J Am Neurol Assoc Child Neurol Soc. 1993;34(2):162-8.

Weinshenker BG, O'Brien PC, Petterson TM, Noseworthy JH, Lucchinetti CF, Dodick DW, et al. A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease. Ann Neurol. 1999;46(6):878-86.

Mandler RN, Ahmed W, Dencoff JE. Devic's neuromyelitis optica: a prospective study of seven patients treated with prednisone and azathioprine. Neurol. 1998;51(4):1219-20.

Bichuetti DB, de Oliveira EM, Oliveira DM, de Souza NA, Gabbai AA. Neuromyelitis optica treatment: analysis of 36 patients. Arch Neurol. 2010;67(9):1131-6.

Pescovitz MD. Rituximab, an anti‐CD20 monoclonal antibody: history and mechanism of action. Am J Transplantation. 2006;6(5p1):859-66.

Yang CS, Yang L, Li T, Zhang DQ, Jin WN, Li MS, et al. Responsiveness to reduced dosage of rituximab in Chinese patients with neuromyelitis optica. Neurol. 2013;81:710-3.

Downloads

Published

2019-07-24

Issue

Section

Original Research Articles